Browsing Tag
North Bristol NHS Trust
1 post
Tempus (Nasdaq: TEM) gains real-world NHS evidence for Paige Prostate AI, but scale-up still depends on economics
Prospective NHS deployment strengthens the clinical case for Tempus AI’s digital pathology portfolio, although cost effectiveness, infrastructure readiness and commercial conversion remain unproven.